About Wharton’s Jelly Therapy
Wharton’s Jelly, one of the latest cellular therapies, has seen major progress in recent years and is projected to see many more applications in future years.
Wharton’s Jelly refers to the gelatinous connective tissue of the umbilical cord, providing insulation and protection to its veins and arteries. The jelly contains no other blood or lymph vessels and is not innervated.
Wharton’s Jelly stem cells, also called Human Umbilical Cord Tissue Mesenchymal Stem Cells (HUCT-MSC) are most known to modulate the immune system, reduce inflammation and secrete factors that may contribute to the regeneration of various tissues throughout the body.
The advantages of Wharton’s Jelly Therapy are twofold:
- Wharton’s Jelly is considered “immunologically privileged,” meaning the host’s immune system is unable to detect HUCT-MSC cells as foreign and are therefore not rejected.
- Wharton’s Jelly stem cells present a more efficient rate of proliferation than stem cells found in the bone marrow. These more “potent” cells lead to better and faster results.
Wharton’s Jelly has been used in the following applications:
- Umbilical cord cellular therapy is said to have anti-bacterial, anti-inflammatory and anti-fibrotic properties, making it a strikingly attractive choice to aid in regenerative therapies.
- Wharton’s Jelly stem cells can grow into bone, cartilage, muscle and fatty tissues.